Shuangcheng Pharmaceutical announced that in the first half of 2026, it achieved operating income of 117 million yuan, a year-on-year increase of 39.27%; net profit attributable to shareholders of listed companies was 13.6.27,800 yuan, a net loss of 184.666 million yuan, an increase of 173.80% in the same period last year; net profit after deducting non-recurring profit and loss was 10.896 million yuan, a net loss of 21.58 million yuan for the same period last year, an increase of 151.86% over the previous year. The company does not pay cash dividends, does not give bonus shares, and does not use the Provident Fund to increase share capital. On May 25, 2026, the company lifted the delisting risk warning, and the stock abbreviation was changed from “*ST Shuangcheng” to “Shuangcheng Pharmaceutical”.

Shuangcheng Pharmaceutical announced that in the first half of 2026, it achieved operating income of 117 million yuan, a year-on-year increase of 39.27%; net profit attributable to shareholders of listed companies was 13.6.27,800 yuan, a net loss of 184.666 million yuan, an increase of 173.80% in the same period last year; net profit after deducting non-recurring profit and loss was 10.896 million yuan, a net loss of 21.58 million yuan for the same period last year, an increase of 151.86% over the previous year. The company does not pay cash dividends, does not give bonus shares, and does not use the Provident Fund to increase share capital. On May 25, 2026, the company lifted the delisting risk warning, and the stock abbreviation was changed from “*ST Shuangcheng” to “Shuangcheng Pharmaceutical”.